Meeder Asset Management’s Tempest Therapeutics TPST Stock Holding History

Meeder Asset Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4	Closed	-$4K	–	2467
2020 Q1	$4K	Buy	4 +3	+300%	+$4.38K	﹤0.01%	1887
2019 Q4	$2K	Hold	1	–	–	﹤0.01%	2062
2019 Q3	$2K	Buy	+1	New	+$1.61K	﹤0.01%	1986
2018 Q4	–	Hold	0	–	-$1K	–	1803
2018 Q3	–	Sell	-2	Closed	-$4.81K	–	1492
2018 Q2	$5.55K	Hold	2	–	–	﹤0.01%	1253
2018 Q1	$4K	Hold	2	–	–	﹤0.01%	1290
2017 Q4	$7K	Hold	2	–	–	﹤0.01%	1233
2017 Q3	$7K	Buy	+2	New	+$8.55K	﹤0.01%	1169
2017 Q2	–	Hold	0	–	–	–	1557
2017 Q1	–	Sell	-1	Closed	-$4.66K	–	1558
2016 Q4	$6K	Buy	+1	New	+$12.5K	﹤0.01%	839

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Meeder Asset Management's TPST Position: Q2 2020 in Review

Meeder Asset Management sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 4 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in TPST in Q4 2016 and held it in 8 quarters. The position peaked at $7K in Q4 2017. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

Meeder Asset Management reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 4 Tempest Therapeutics shares in Q2 2020, an estimated $4K.
Meeder Asset Management first reported a position in Tempest Therapeutics in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Tempest Therapeutics position peaked at $7K in Q4 2017.
51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.